Industry News

Latest orthopaedic industry news on orthopaedic companies, devices, implants & technology trends.

We are excited to announce the opening of a brand new state-of-the-art bioskills in Boston - Boston Bioskills Lab.

Read more ...

Kleinostheim, 05.12.2012 – curasan AG, listed on the General Standard (ISIN: DE 000 549 453 8), has introduced its new bone regeneration material CERASORB® Ortho Paste to the German and European markets at the beginning of December. CERASORB® Ortho Paste is comprised of fine granules of the proven, fully resorbable, synthetic material CERASORB® M Ortho suspended in a hyaluronic acid hydrogel-matrix. The paste-like product has the advantage that it is pre-packaged in a single-use syringe and does not require any mixing or complicated preparation in order to be applied to the bone defect.

Read more ...

Results from a pre-specified pooled analysis of the RECORD clinical trial program confirmed that the novel oral anticoagulant Xarelto® (rivaroxaban), taken as one tablet, once-daily, was superior to enoxaparin-based treatment regimens for the prevention of venous thromboembolism (VTE) after total knee or hip replacement surgery with low rates of major bleeding that were not statistically different from the comparator.

Read more ...

Health Canada has just approved Xarelto® (rivaroxaban) for the prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip or total knee replacement surgery. This marks the first approval for Xarelto worldwide. For the first time in the world, the new oral, once-daily anticoagulant Xarelto is to be made commercially available to patients in Canada In July 2008, the CHMP issued a positive opinion and recommended approval of rivaroxaban in the EU for the prevention of venous blood clots in patients undergoing elective total hip or total knee replacement surgery. A final decision is expected very soon Xarelto is the most studied oral, direct Factor Xa inhibitor in the world today Xarelto is being jointly developed by Bayer HealthCare and Johnson & Johnson Pharmaceutical Research & Development, L.L.C.  

Read more ...

Biomet, a major manufacturer of artificial hips and knees, said on December 18th that it had agreed to a $10.9 billion buyout offer from a private investment consortium. The bid came from affiliates of the Blackstone Group, Goldman Sachs Capital Partners, Kohlberg Kravis Roberts & Company and the Texas Pacific Group. Biomet said the private investment group was also expected to include Dane A. Miller, a co-founder of Biomet in 1977 and its longtime chief executive until he resigned in April, citing disagreements with the board.

Read more ...

Kleinostheim, Germany, September 4th, 2009 – curasan AG, listed on the General Standard of Deutsche Börse AG as ISIN: DE 000 549 453 8, has just received a grant of €1.48 million from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) for a bone regeneration research project scheduled to last three years. The funds are earmarked for a joint project with Ben Gurion University (BGU) of the Negev, Israel.

Read more ...

A new study was presented at the 4th Annual Congress of the German Spine Society in Munich - it demonstrated the long-term effect of Curavisc® in the treatment of chronic facet syndrome 

Read more ...

27% of Medical Device Industry Executives Will "Definitely" Pursue New Employment in 2010; 28% Indicate "Strong Possibility."  Only 22% are committed to staying in current role. According to a poll of 2000 medical industry professionals randomly surveyed January 4-7, 2010, more than half are looking at 2010 as the year to make a job change.

Read more ...

Already a highly sought after physician who works with the Tampa Bay Buccaneers and US Olympic Team, Coastal Orthopedics surgeon Daniel Lamar, MD is bringing his sports medicine expertise to the Manatee High School athletic program.  A former starting wide receiver for Coach Joe Kinnan and the Manatee High Hurricanes, Dr. Lamar has kept his eye on the football team's progress since graduating from high school.

Read more ...

curasan AG expects to make a considerable profit instead of the two million euro loss announced for the financial year 2010

Read more ...

Submit Community Content

If you have orthopedic information that you would like to share with the Orthogate Community, please register/login and submit your news, event, job, article, case or workshop from the Submit Content menu under the My Account area. Learn more!